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LiposomeThe organic cation transporter (OCTN1) plays key roles in transport of selected organic cations, but understand-
ing of its biological functions remains limited by restricted knowledge of its substrate targets. Here we show
capacity of human OCTN1-reconstituted proteoliposomes to mediate uptake and efﬂux of [3H]acetylcholine,
the Km of transport being 1.0 mM with Vmax of 160 nmol⋅mg−1 protein⋅min−1. OCTN1-mediated transport of
this neurotransmitter was time-dependent and was stimulated by intraliposomal ATP. The transporter operates
as uniporter but translocates acetylcholine in both directions. [3H]acetylcholine uptakewas competitively inhib-
ited by tetraethylammonium, γ-butyrobetaine and acetylcarnitine, and was also inhibited by various
polyamines. Decreasing intraliposomal ATP concentrations increased OCTN Km for acetylcholine, but Vmax was
unaffected. Evaluation of the acetylcholine transporter properties of a variant form of OCTN1, the Crohn's
disease-associated 503F variant, revealed time course, Km and Vmax for acetylcholine uptake to be comparable
to that of wild-type OCTN1. Km for acetylcholine efﬂux was also comparable for both OCTN1 species, but Vmax
of OCTN1 503F-mediated acetylcholine efﬂux (1.9 nmol⋅mg−1 protein⋅min−1) was signiﬁcantly lower than
that of wild-type OCTN1 (14 nmol⋅mg−1 protein⋅min−1). These data identify a new transport role for OCTN1
and raise the possibility that its involvement in the non-neuronal acetylcholine system may be relevant to the
pathogenesis of Crohn's disease.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
The OCTN1 protein belongs to a small family of transporter pro-
teins – the organic cation transporters – which share more than 66%
identity with one another [1]. These proteins originated after the diver-
gence of vertebrates and invertebrates [2]. Deﬁnition of OCTN1
substrates began many years ago [1,3–6], but has been greatly en-
hanced recently by capacity to reconstitute in proteoliposomes the
human OCTN1 overexpressed in bacteria [7,8]. The transporter has
been inserted into the proteoliposomalmembranewith the sameorien-
tation as in the cell membrane. Via use of this experimental system,
tetraethylammonium (TEA), has been identiﬁed as very good substrate
for OCTN1 transporter. In this system, OCTN1 has been shown to trans-
port TEA with eight fold more efﬁciency than some of its otherxal 5-phosphate; ANTP, adeno-
ethylammonium)ethyl metha-
EM, N-ethylmaleimide
llulare Università della Calabria,
Italy. Tel.: +39 0984 492939;
rights reserved.previously-identiﬁed substrates such as ergothioneine [5] and carnitine
[6]. The data performedwith the reconstituted transporter diverge from
some data reported in intact cells, however, they are consistent with
other data performed with intact cells [1,3,4]. Availability of reconsti-
tuted hOCTN1 has also enabled better deﬁnition of other aspects of its
transport properties, revealing its interaction with not only known
substrates such as tetraethylammonium and acetylcarnitine, but also
with a number of new species, including the neurotransmitter acetyl-
choline. While best recognized for its neurotransmitter functions,
acetylcholine has recently emerged as an important player in the non-
neuronal cholinergic system [9,10]. This system includes the airways,
alimentary tract, skin, placenta, heart, skeletal muscle, urogenital tract
and other tissues now known to express choline acetyltransferase as
well as acetylcholine receptor and degrading enzyme, cholinesterase
[9]. Within these tissues, roles for acetylcholine in cell proliferation
and differentiation, cytoskeletal organization, cell–cell contact and
even inﬂammation are now appreciated [9]. Acetylcholine involvement
in these processes requires its transport into or efﬂux from the relevant
cells. However, differently from the nervous tissues in which a trans-
porter for acetylcholine has been described [11], until now, the mecha-
nisms for acetylcholine trafﬁcking in non-nervous system cells have
remained unknown. Recent data, however, suggesting that OCTN1 [8]
Fig. 1. Time course of acetylcholine uptake by reconstituted proteoliposomes. The recon-
stitution was performed as described in Materials and methods. Transport was started
adding 0.1 mM [3H]acetylcholine at time zero to proteoliposomes (●,■,○) or proteolipo-
somes reconstituted with protein treated for 20 min at 100 °C (□). In (■) 2 mM acetyl-
choline was present inside the proteoliposomes. In (●) the transport reaction was
stopped at the indicated times and the speciﬁc transport activity was calculated according
to the inhibitor stop-method. In (□, ■,○), the transport reaction was stopped at the
indicated times by directly passing the proteoliposomes through Sephadex G-75 columns
as described inMaterials andmethods and the speciﬁc transport activitywas calculated as
the difference between the uptake in the presence and absence of incorporated protein
(not reported). The values are means±S.D. from three experiments.
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acetylcholine transporter as previously found also for members of the
OCT transporter family which mediate acetylcholine transport in pla-
centa [9] and other tissues [12,13]. By assessing effects of hOCTN1
reconstituted into liposomes, on acetylcholine transport, we demon-
strate here that OCTN1 modulates uptake and efﬂux of acetylcholine
and that its capacity to transport this molecule is altered by the L503F
substitution associated with inﬂammatory bowel disease [14].
2. Materials and methods
2.1. Materials
Amberlite XAD-4, egg yolk phospholipids (3-sn-phosphatidylcoline
from egg yolk) and Triton-X100were purchased from Fluka; acetylcho-
line iodide [acetyl-3H] from Perkin-Elmer, Sephadex G-75, L-carnitine,
tetraethylammonium chloride from Sigma, ergothioneine from Santa
Cruz Biotechnology. All the other reagents were of analytical grade.
2.2. Reconstitution of the hOCTN1 transporter into liposomes
hOCTN1 and hOCTN1 503F were over-expressed in E.coli and
puriﬁed as previously described [7] with the exception that the NaCl
concentration in the buffer used for the elution of the puriﬁed protein
fraction, was 50 mM instead of 200 mM. This resulted in an increase
of the transport activity of the hOCTN1 with respect to the previous
procedure [8] with no variations in the amount and purity of the
protein. The puriﬁed hOCTN1 and hOCTN1 503F were reconstituted
by removing the detergent from mixed micelles containing detergent,
protein and phospholipids by incubation with Amberlite XAD-4 in a
batch-wise procedure [8]. The composition of the initial mixture used
for reconstitution (except when differently indicated) was: 180 μl of
the puriﬁed protein (6 μg protein in 0.1% Triton-X100), 120 μl of 10%
Triton X-100, 120 μl of 10% egg yolk phospholipids in the form of
sonicated liposomes prepared as previously described [15], 16 mM
ATP di-sodium salt buffered at pH 8.0, 10 mM Tris/HCl (pH 8.0) in a
ﬁnal volume of 700 μl. After vortexing, this mixture was incubated
with 0.55 g Amberlite XAD-4 under rotatory stirring (1400 rpm) at
room temperature for 45 min.
2.3. Transport measurements
Proteoliposomes (550 μl) were passed through a Sephadex G-75
column (0.7 cm diameter×15 cm height) preequilibrated with 10 mM
Tris/HCl (pH 8.0). Proteoliposomes (550 μl) were collected from these
columns and divided in aliquots (samples) of 100 μl. Transport was
started by adding the indicated concentrations of [3H]acetylcholine to
the proteoliposome samples, as indicated in the ﬁgure legends and
stopped by adding 2 mM PLP at the desired time interval. In control
samples the inhibitor was added at time zero according to the inhibitor
stop method [16]. The assay temperature was 25 °C. Finally, each
sample of proteoliposomes (100 μl) was passed through a Sephadex
G-75 column (0.6 cm diameter×8 cm height) in order to separate the
external from the internal radioactivity. Liposomes were eluted with
1 ml 50 mMNaCl and collected in 4 ml of scintillationmixture, vortexed
and counted. The experimental values were corrected by subtracting
the respective control. The PLP insensitive radioactivity associated to
the control samples was always less than 15% with respect to the PLP
sensitive acetylcholine transport. The initial rate of transport expressed
as nmol ⋅mg−1 protein ⋅min−1, wasmeasured by stopping the reaction
after 5 min, i.e., within the initial linear range of [3H]acetylcholine
uptake into the proteoliposomes (see Fig. 1). For efﬂux measurements,
aliquots of the same pool of proteoliposomes were incubated with
external [3H]acetylcholine at different concentrations. After 90 min,
corresponding to the optimal intraliposomal [3H]acetylcholine accumu-
lation the proteoliposomes were passed again trough a Sephadex G-75column (0.7 cm diameter×15 cm height) preequilibrated with 10 mM
Tris/HCl (pH 8.0) and the time course of [3H]acetylcholine efﬂux was
then measured as described for the uptake procedure. The efﬂux reac-
tion was stopped at the indicated time intervals by adding 2 mM PLP.
The uptake time course data were interpolated using a ﬁrst order rate
equation from which rate constants were derived as the product of k
(the ﬁrst order rate constant) and the transport at the equilibrium.
The efﬂux time course datawere interpolated using a single exponential
decay equation fromwhich the initial rates of the efﬂuxwere calculated
as the product of k (theﬁrst order rate constant) and the amount of [3H]
acetylcholine efﬂuxed at inﬁnite time (equilibrium). The concentration
of internal [3H]acetylcholine at the beginning of the efﬂux procedure
was equal to the initial external [3H]acetylcholine concentration.
Kinetic constants were estimated using non linear ﬁtting of the
experimental data in the Michaelis–Menten equation. Lineweaver–
Burk plots were used for presentation of inhibition. The Graﬁt (version
5.0.3) software was used for calculations.
2.4. Other methods
Protein amount wasmeasured by densitometry of Coomassie-stained
protein bands carried out using the Chemidoc imaging system equipped
with Quantity One software (Bio-Rad), as previously described [17].
Sequence motifs were predicted by the Prosite tool.
3. Results
3.1. hOCTN1 mediates acetylcholine transport
Uptake of [3H]acetylcholine in hOCTN1-reconstituted proteolipo-
somes was initially measured as a function of time (Fig. 1), with PLP
used to terminate transport. This analysis revealed acetylcholine
uptake to be signiﬁcantly higher in hOCTN1 compared to “empty”
(no hOCTN1-containing; control) liposomes (not shown) with the
rate of transport being 30±7.8 nmol⋅mg−1 protein⋅min−1. These
values appear to accurately reﬂect speciﬁc acetylcholine transport
activity as the observed time course of transport activity mirrored
that calculated by subtracting the control values. To gain insights
into mode of transport, [3H]acetylcholine uptake into acetylcholine-
loaded hOCTN1-containing liposomes was also evaluated. As this
analysis revealed speciﬁc transport to be similar or slightly lower in
the presence compared to absence of internal substrate, it appears
that the transporter catalyzes uniport rather than antiport. Comparison
Table 1
Effect of different substrates on the reconstituted hOCTN1. Transport was measured as
0.1 mM [3H]acetylcholine uptake into proteoliposomes, reconstituted as described in
Materials and methods, in 10 min. The molecules were added 1 min before the labeled
substrate at the indicated concentrations. Percent residual activity was calculated for
each experiment with respect to the control sample (referred as 100%). The results
are means±S.D. of the percentage of three experiments.
Substrate Concentration (mM) Residual activity (%)
acetylcarnitine 0.5 46±15a
1.0 24±0.9a
carnitine 0.5 90±2.6a
1.0 80±11
tetraethylammonium 0.5 66±9.8a
1.0 49±5.3a
choline 0.5 60±2.8a
1.0 40±6.9a
betaine 0.5 86±10
1.0 83±2.3a
ergothioneine 0.5 90±4.9
1.0 67±3.2a
tetramethylammonium 0.5 54±8.3a
1.0 44±2.9a
glucose 0.5 80±24
1.0 80±3.5a
creatinine 0.5 75±0.4a
1.0 74±10
creatine 0.5 94±1.9
1.0 78±4.1a
γ-aminobutyric acid 0.5 78±6.6a
1.0 63±1.2a
γ-butyrobetaine 0.5 45±5.1a
1.0 27±6.3a
spermine 0.5 6.8±1.5a
spermidine 0.5 7.4±3.5a
a Signiﬁcantly different from the control (100%) as estimated by Student's t test
(Pb0.05).
561L. Pochini et al. / Biochimica et Biophysica Acta 1818 (2012) 559–565of the acetylcholine transporter activity of boiled versus native hOCTN1 in
this system revealed much lower transport of the boiled protein, indicat-
ing that hOCTN1 activity is required for its transport of acetylcholine.
Transport activity was also increased by raising pH from 6.0 (activity
near zero) to 7.5 and remained nearly constant under pH conditions of
7.5–8.5 (not shown).
It was previously hypothesized in experiments performedwith cells
that ATP may stimulate hOCTN1 transport activity [18]. Indeed, TEA
uptake catalyzed by reconstituted hOCTN1was stimulated by intralipo-
somal ATP [8]. Thus the effect of ATP on hOCTN1-mediated acetylcho-
line transport was evaluated. For this purpose the transport assays
were performed in proteoliposomes reconstituted with varying
concentrations of ATP (Fig. 2). A biphasic pattern of transport was
observed, with activity plateauing initially at 6 mM ATP and again at
12 mM ATP. This effect, which was also previously reported in relation
to TEA transport, was not due to ATP hydrolysis, as the same pattern
was observed in tests using non-hydrolysable ATP analog (ANTP) rather
than ATP (data not shown). Moreover, the activation by intraliposomal
ATPwas rather speciﬁc since internal adenosine, AMP and cAMPdid not
exert appreciable effects and no variations of transport activity respect
to the condition with zero internal ATP were observed in the presence
of internal NaCl or sucrose at concentrations ranging from 5 to 50 mM
(not shown). Differently from the intraliposomal side, ATP externally
added did not exert any activation effect (Fig. 2).
To explore the effects of other compounds on this transport path-
way, the hOCTN1-reconstituted liposomeswere next assayed for capac-
ity to transport acetylcholine in the presence of other knownor putative
OCTN1 substrates or inhibitors. Among the substrates tested, carnitine,
betaine, ergothioneine, glucose, creatinine, creatine and GABA had no
effect on acetylcholine transport when used at concentrations up to
1 mM (Table 1). By contrast, acetylcholine transport was almost
completely inhibited by spermine and spermidine at concentrations
as low as 0.5 mM and was also signiﬁcantly suppressed by choline,
acetylcarnitine, γ-butyrobetaine, tetraethylammonium and tetra-
methylammonium. Similarly, HgCl2, MTSET and pOHMB, compounds
known to interact with SH residues, as well as PLP, which interacts
with NH2 residues, all inhibited the transporter to varying degrees
(Table 2 and Fig. 3). These inhibitory effects appeared speciﬁc to indi-
vidual compounds, as transport activity was not affected by two other
reagents, NEM and mersalyl, which also recognize SH residues. The
effects of PLP, the inhibitor used in most of our transport assays, were
concentration-dependent, acetylcholine transport being entirely
abrogated at PLP concentration of 1.5 mM and IC50 being 0.39±
0.051 mM (Fig. 3).Fig. 2. Dependence of acetylcholine transport on the concentration of intra- and extra-
liposomal ATP. The reconstitution was performed as described in Materials and methods
except that the indicated concentrations of ATP were added to the reconstitutionmixture
(○) or to the external side of proteoliposomes without internal ATP (●). Transport was
started adding 0.1 mM [3H]acetylcholine to proteoliposomes. The values are means±
S.D. from three experiments.3.2. Kinetics of hOCTN1-mediated acetylcholine transport
The kinetics of hOCTN1-mediated acetylcholine transport were also
explored, these assays measuring uptake of varying concentrations of
[3H]acetylcholine by the hOCTN1-reconstituted liposomes. This analy-
sis revealed the half saturation constant (Km) to be 1.0±0.21 mM
and Vmax to be 160±32.0 nmol⋅mg−1 protein⋅min−1. Similar studies
were also carried out in the context of added substrates or inhibitors
so as to delineate the extent to which these compounds modulate the
kinetics of acetylcholine transport. As shown in Fig. 4, these analyses
revealed competitive inhibition of acetylcholine transport by TEA,
γ-butyrobetaine and acetylcarnitine and mixed inhibition by spermi-
dine and spermine. The kinetic constants are summarized in Table 3.
ATP effects on acetylcholine kinetics were also assessed measuring theTable 2
Effect of inhibitors on the reconstituted hOCTN1. Transport was measured as 0.1 mM
[3H]acetylcholine uptake into proteoliposomes, reconstituted as described in Materials
and methods, in 10 min. The molecules were added 1 min before the labeled substrate
at the indicated concentrations. Percent residual activity was calculated for each exper-
iment with respect to the control sample (referred as 100%). The results are means
±S.D. of the percentage of three experiments.
Inhibitor Concentration (mM) Residual activity (%)
mersalyl 0.1 128±18
1.0 84±6.8
NEM 0.5 96.7±11
1.0 92.3±0.9
HgCl2 0.02 57±3.9a
0.2 13±0.3a
p-OHMB 0.02 65±6.7a
0.2 25±12a
MTSET 0.1 93±4.1
1.0 38±3.2a
a Signiﬁcantly different from the control (100%) as estimated by Student's t test
(Pb0.05).
Fig. 3. Dose–response curves for the inhibition of the reconstituted transporter by PLP.
Transport was measured by adding 0.1 mM [3H]acetylcholine to proteoliposomes in the
presence of PLP at the indicated concentrations. Percent residual activity with respect to
the control is reported. The values are means±S.D. from three experiments.
Table 3
Inhibition kinetic data of hOCTN1. Kinetic constants calculated from the experiments
described in Fig. 4 A and B. Values are obtained by non linear regression analysis of
means from at least three different experiments. For each data S.D. is reported which
was obtained by non linear regression to each data set.
Inhibitor Km or Ki Vmax (nmol ∙mg−1 ∙min-1)
No inhibitor (Km for acetylcholine) 1.0±0.21 mM 160±32
TEA 1.3±0.31 mM
γ-butyrobetaine 0.70±0.32 mM
Acetylcarnitine 0.72±0.25 mM
Spermidine 35±7.1 μM
Spermine 18±2.4 μM
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presence of 16 mM internal ATP, i.e., the condition used for all the other
experiments, or 4 mM ATP. At the lower ATP concentration the Km of
OCTN1 for acetylcholine was higher (1.6 mM) than at 16 mM ATP,
whereas the Vmax did not change (Fig. 5).
3.3. The hOCTN1 503F mutant impairs hOCTN1-mediated acetylcholine
transport
In previous studies of hOCTN1 activity, a variant form of hOCTN1
(503F mutant) associated with predisposition to Crohn's disease has
been shown to alter hOCTN1-mediated TEA transport [14]. The effects
of this variant on hOCTN1 acetylcholine transporter activity were thus
assayed using proteoliposomes reconstitutedwith hOCTN1 503 F. Results
of a time course assay (Fig. 6) revealed rate of [3H]acetylcholine uptakeFig. 4. Kinetic analysis of the inhibition of the reconstituted transporter by TEA, acetylcar-
nitine,γ-butyrobetaine and polyamines. The transport ratewasmeasured, as described in
Materials and methods adding [3H]acetylcholine at the indicated concentrations to
proteoliposomes in the absence (○) or presence of (A) 0.5 mM TEA (□), 0.4 mM acetyl-
carnitine (●) or 0.5 mM γ-butyrobetaine (■); (B) 40 μM spermidine (●) or 40 μM
spermine (□). Data were plotted according to Lineweaver–Burk as reciprocal transport
rate vs reciprocal acetylcholine concentration. The values are means±S.D. from three
experiments.mediated by the mutant hOCTN1 species to be similar to that of wild-
type, the transport rate being 33±5.2 nmol⋅mg−1 protein⋅min−1. As
for wild-type, hOCTN1 503 F-mediated transport rate was affected by
acetylcholine concentration, with Km being 0.47±0.10 mM and
Vmax=177±17 nmol⋅mg−1 protein⋅min−1 (Fig. 7). Capacity for trans-
port in the opposite direction, i.e. efﬂux from the cell, was then assayed
in proteoliposomes containing either wild-type or mutant hOCTN1. This
assay conﬁrmed capacity of wild-type hOCTN1 to mediate counter-
transport of [3H]acetylcholine, the residual radioactivity inside the
proteoliposome providing a measure of the extent of efﬂux (Fig. 8). For
wild-type hOCTN1, a rate of efﬂux of 3.6±0.88 nmol⋅mg−1 protein⋅-
min−1 was observed, a value lower than the rate of acetylcholine uptake.
Efﬂux of [3H]acetylcholine from the hOCTN1 503 F-proteoliposomeswas,
however, even lower, the rate of transport being 0.41±0.1 nmol⋅mg−1
protein⋅min−1. This apparent defect in driving [3H]acetylcholine efﬂux
was further studied using proteoliposome containing varying concentra-
tions of [3H]acetylcholine. As observed for substrate uptake, rates at
which internal acetylcholine was transported outwards were
concentration-dependent. The wild-type hOCTN1 exhibited a Km of
0.78±0.14 mM and Vmax of 14±2.0 nmol⋅mg−1 protein⋅min−1
(Fig. 9A); the hOCTN1 503 F species showed Km of 0.54±0.10 mM and
Vmax of 1.9±0.40 nmol⋅mg−1 protein⋅min−1. Thus the variantmanifests
a signiﬁcant impairment in capacity to transport acetylcholine substrate
from the proteoliposomes, i.e. from the cell.
4. Discussion
The experimental model of reconstitution in liposomes allows to
obtain reliable information on the function of transporters in absence
of interferences by other transporters or enzymes [8,19–23]. Further-
more, the reconstitution is an essential tool for studying heterologously
expressed human transporterswhich cannot be studied after extraction
from tissues [8,24–27]. The functional properties of the reconstitutedFig. 5. Kinetic analysis of the acetylcholine transport in the presence of different intralipo-
somal ATP concentrations. The transport ratewasmeasured, as described inMaterials and
methods adding [3H]acetylcholine at the indicated concentrations to proteoliposomes
containing 16 mM (○) or 4 mM (●) ATP. Data were plotted according to Lineweaver–
Burk as reciprocal transport rate vs reciprocal acetylcholine concentration. The values
are means±S.D. from three experiments.
Fig. 6. Time course of acetylcholine uptake by proteoliposomes reconstituted with the
L503F hOCTN1 in comparison with WT. The reconstitution was performed as described
in Materials and methods. Transport was started adding 0.1 mM [3H]acetylcholine at
time zero to proteoliposomes. The transport reaction was stopped at the indicated times
according to the inhibitor stop-method. Data from Fig. 1 concerning the WT (●) was
also reported together with the mutant L503F (○). The values are means±S.D. from
three experiments.
Fig. 8. Time course of acetylcholine efﬂux from proteoliposomes catalyzed by the recon-
stituted wild type and mutant transporters. [3H]acetylcholine efﬂux was measured from
proteoliposomes reconstitutedwith thewild type (○) or L503Fmutant (●) after prelabel-
ling by transporter-mediated exchange equilibration; the transport reaction was stopped
at the indicated times as described inMaterials andmethods. The values are means±S.D.
from three experiments.
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some authors in cells [1,3,4]. The reconstituted transporter seems to be
in a native form, i.e., properly folded, since the kinetic constants for
TEA are similar to those reported in transfected cells. However, somedif-
ferences were found for ergothioneine respect to data obtained in cell
systems, which may be due to different experimental conditions in the
measurement of transport, i.e., lack of regulatory factors in proteolipo-
somes, exerting speciﬁc effects in cells on ergothioneine transport [8].
Concerning the side-speciﬁcity (intraliposomal) of the ATP effect
(Fig. 2), thismay be in agreementwith the orientation of the transporter
in the liposomal membrane as in the cell membrane [8]. The functional
asymmetry of the transporter corresponds to the structural asymmetry;
interestingly the analysis of the sequence of hOCTN1 reveals a nucleo-
tide bindingmotif, which is intracellularly located as deduced by the hy-
dropathy proﬁle of the protein [7] (see also Fig. 10). However, all the
experimental data concerning the OCTN1 function described so far [3–
6], does not account for a speciﬁc physiological function of this trans-
porter. Among the proposed OCTN1 substrates, TEA is a non physiolog-
ical prototype cation, ergothioneine is an exogenous compound and
carnitine was found by several authors to be transported at a very low
rate [1, 3–6, 8]. The experimental data described in this work, shows
that hOCTN1 catalyzes both uptake and efﬂux of acetylcholine. The Km
for acethylcholine is very similar to that previously reported for the ve-
sicular acetylcholine transporter VAchT [28], indicating that hOCTN1
should be suitable to mediate acetylcholine transport in vivo. The Vmax
of hOCTN1 is comparable to that of another reconstituted human trans-
porter, the organic cation transporter MATE 2 [27], whichmediates TEAFig. 7. Kinetic analysis of the acetylcholine transport catalyzed by the L503F hOCTN1. The
transport rate was measured, as described in Materials and methods adding [3H]acetyl-
choline at the indicated concentrations to proteoliposomes reconstituted with the L503F
hOCTN1. Datawere plotted according toMichaelis–Menten as transport rate vs acetylcho-
line concentration. The values are means±S.D. from three experiments.transport as the hOCTN1. The similar Km on the external and internal
membrane side of hOCTN1, indicated that external and internal binding
sites may be assembled by common amino acid residues, alternatively
exposed outside or inside, depending on the conformational state (out-
wardly or inwardly directed) of the transporter. The lower Vmax found in
the outward transport direction with respect to the inward may be
explained bydifferent activation energies associatedwith the conforma-
tional changes required for the two opposed transport processes or, al-
ternatively, the two processes might be differently modulated by
effectors, such as ATP. Kinetic analysis revealed that ATP slightly modu-
lates the Km, i.e., the substrate–transporter interaction not the intrinsic
transport activity (Vmax), indicating that the nucleotide inﬂuences theFig. 9. Kinetic analysis of the acetylcholine efﬂux catalyzed by the reconstitutedwild type
and mutant transporters. [3H]acetylcholine efﬂux rate was measured from proteolipo-
somes reconstituted with the wild type (A) or L503F mutant (B) after prelabelling by
transporter-mediated exchange equilibration with different [3H]acetylcholine concentra-
tions, as described in Materials and methods. Data were plotted according to Michaelis–
Menten as transport rate vs intraliposomal acetylcholine concentration (mM). The values
are means±S.D. from three experiments.
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Fig. 10. Topology of hOCTN1 with 12 transmembrane α-helices and a large extracellular loop. The model was created on the basis of the TM-PRED prediction software (output format:
min 17, max 29) andmodiﬁed considering the established criteria for trans-membrane proteins. Transmembrane segments are numbered (1–12). Location of themutated L503F residue
of the Crohn's variant OCTN1 is indicated by a box in the transmembrane segment 12. The predicted nucleotide binding motif GTEILGKS is highlighted (boxed).
564 L. Pochini et al. / Biochimica et Biophysica Acta 1818 (2012) 559–565conformation of the substrate binding site. The physiological implication
of the acetylcholine transport function of hOCTN1 can be interpreted in
the light of the newly described non-neuronal cholinergic system [9,10].
Indeed, in contrast to the release of neuronal acetylcholine via exocyto-
sis, the mechanisms of acetylcholine trafﬁcking through non-neuronal
membranes are still poorly understood. Furthermore VAchT, the vesicu-
lar acetylcholine transporter, is not present in all the tissues of the non-
neuronal cholinergic system [11]. It has been previously suggested, that
OCT1 and OCT2 transporters are involved in acetylcholine transport in
placenta [9], in bronchial epithelium and in brain [13]. However, these
transporters are not expressed in all the tissues in which acetylcholine
is synthesized [9,29,30]. In these tissues, i.e., trachea, kidney, prostate,
testis, sperm, spinal cord, bonemarrow,muscle cells, granulocytes, lym-
phocytes and macrophages [13,31] OCTN1 has high level of expression,
thus, playing an important role in the acetylcholine trafﬁcking. Other
considerations, i.e., the Km's of hOCTN1 and OCT2 [13,30] for acetylcho-
line are different, hOCTN1 catalyzes efﬂux, the sub-localizations of OCT2
andOCTN1 are different [14,30], suggest that the concerted action of the
different transporters may be essential for the overall regulation of the
trafﬁcking of acetylcholine in tissues where both of them are expressed.
Furthermore, OCTN1 may be involved in the recycling of acetylcholine
when it is not hydrolysed by esterase, especially in non-nervous tissues
where acetylcholine esterases have lower activity [29]. Interestingly, it
has been recently reported that acetylcholine may play an important
role in inducing anti-inﬂammatory effects via α7-nAChRs which are
expressed in several non neuronal tissues [9,29]. To play this autocrine
effect, acetylcholine needs to be exported from the cells [29]. The intra-
cellular acetylcholine concentration in non-neuronal tissues has not yet
been determined, while in neuronal tissues it has been reported to be
around 1 mM [28]. Thus, it is plausible that the autocrine effect may beexerted by the efﬂux of acetylcholine and, even in the presence of
intracellular concentration lower than 1 mM, corresponding about to
the Km of the internal side of hOCTN1, the efﬂux should provide sufﬁ-
cient acetylcholine for high-afﬁnity interaction with the α7-nAChRs
receptor. Thus, the efﬂux function will have importance in this scenario.
The inhibition of the transport by polyaminemay play an additional role
in the inﬂammatory process. Indeed, spermine concentration increases
in tissues during inﬂammation due to release from dying cells and
plays antinﬂammatory actions [32]. The strong inhibition of hOCTN1
by polyamines may reduce acetylcholine uptake in cells, prolonging its
antinﬂammatory effect concomitantly with that of polyamines. Of
note, the export function is speciﬁcally impaired in the hOCTN1 mutant
503F which has been correlated with the inﬂammatory bowel disease
and Crohn's disease [14]. The mutation affects the transmembrane
segment 12 of the protein (Fig. 10). Similarly, structural alterations of
transmembrane segments 4, 7 and 11 of the OCTN2 transporter caused
by gene mutations, result in functional impairments [33–35]. In the
case of hOCTN1 the substitution of Leu-503 with Phe, reduces the Vmax
without affecting signiﬁcantly the Km, indicating that the substrate
binding site is not modiﬁedwhereas the conformational changes neces-
sary for substrate efﬂux from the vesicles are impaired. It is very unlike
that the reduced function may be due to reduced incorporation into
liposomes, since the uptake catalyzed by the L503F mutant is nearly
coincident to that of the wild type (see Fig. 6). The above ﬁndings may
have broad pathophysiological implications. For instance, given the
reported roles of non-neuronal acetylcoline inmaintaining epithelial in-
tegrity and cell–cell interaction [36], our ﬁnding may link defective ex-
port of acetylcoline by the hOCTN1 503F variant with a compromised
intestinal–pathogen barrier, as it is observed in inﬂammatory bowel dis-
ease. This and similar hypotheses will be object of further experimental
565L. Pochini et al. / Biochimica et Biophysica Acta 1818 (2012) 559–565investigation in cellular and animal experimentalmodels. The studies on
acetylcholine transport conﬁrmed the previous ﬁnding that hOCTN1
may be involved in the transport of γ-butyrobetaine [8] synthesized
by the gut microbioma [37,38] in the intestine, where hOCTN1 is highly
expressed. It has also been found that acetylcarnitine, but not carnitine,
strongly inhibited the transport of acetylcholine conﬁrming that
hOCTN1may also be involved in the transport of acetylated compounds
which are important in the metabolic regulation [39].Acknowledgement
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